447 related articles for article (PubMed ID: 36357543)
21. Cannabis: are there any benefits?
Vickery AW; Finch PM
Intern Med J; 2020 Nov; 50(11):1326-1332. PubMed ID: 33215831
[TBL] [Abstract][Full Text] [Related]
22. Cannabinoids for Treatment of MS Symptoms: State of the Evidence.
Rice J; Cameron M
Curr Neurol Neurosci Rep; 2018 Jun; 18(8):50. PubMed ID: 29923025
[TBL] [Abstract][Full Text] [Related]
23. Cannabinoids: Medical implications.
Schrot RJ; Hubbard JR
Ann Med; 2016; 48(3):128-41. PubMed ID: 26912385
[TBL] [Abstract][Full Text] [Related]
24. [Efficacy, tolerability and safety of cannabinoids for chronic neuropathic pain: A systematic review of randomized controlled studies].
Petzke F; Enax-Krumova EK; Häuser W
Schmerz; 2016 Feb; 30(1):62-88. PubMed ID: 26830780
[TBL] [Abstract][Full Text] [Related]
25. Medical Marijuana and Chronic Pain: a Review of Basic Science and Clinical Evidence.
Jensen B; Chen J; Furnish T; Wallace M
Curr Pain Headache Rep; 2015 Oct; 19(10):50. PubMed ID: 26325482
[TBL] [Abstract][Full Text] [Related]
26. Clinical uses of cannabis and cannabinoids in the United States.
Levinsohn EA; Hill KP
J Neurol Sci; 2020 Apr; 411():116717. PubMed ID: 32044684
[TBL] [Abstract][Full Text] [Related]
27. Cannabinoids and Pain for the Plastic Surgeon: What Is the Evidence?
Stephens KL; Heineman JT; Forster GL; Timko MP; DeGeorge BR
Ann Plast Surg; 2022 Jun; 88(5 Suppl 5):S508-S511. PubMed ID: 35502947
[TBL] [Abstract][Full Text] [Related]
28. Medicinal Properties of Cannabinoids, Terpenes, and Flavonoids in Cannabis, and Benefits in Migraine, Headache, and Pain: An Update on Current Evidence and Cannabis Science.
Baron EP
Headache; 2018 Jul; 58(7):1139-1186. PubMed ID: 30152161
[TBL] [Abstract][Full Text] [Related]
29. Oral THC:CBD cannabis extract for refractory chemotherapy-induced nausea and vomiting: a randomised, placebo-controlled, phase II crossover trial.
Grimison P; Mersiades A; Kirby A; Lintzeris N; Morton R; Haber P; Olver I; Walsh A; McGregor I; Cheung Y; Tognela A; Hahn C; Briscoe K; Aghmesheh M; Fox P; Abdi E; Clarke S; Della-Fiorentina S; Shannon J; Gedye C; Begbie S; Simes J; Stockler M
Ann Oncol; 2020 Nov; 31(11):1553-1560. PubMed ID: 32801017
[TBL] [Abstract][Full Text] [Related]
30. Use and Reported Helpfulness of Cannabinoids Among Primary Care Patients in Vermont.
Wershoven N; Kennedy AG; MacLean CD
J Prim Care Community Health; 2020; 11():2150132720946954. PubMed ID: 32757826
[No Abstract] [Full Text] [Related]
31. [Cannabinoids for the treatment of chronic pain - an overview of current medical knowledge].
Gras-Ozimek J; Kozińska U; Gras-Ozimek A
Pol Merkur Lekarski; 2022 Aug; 50(298):257-261. PubMed ID: 36086988
[TBL] [Abstract][Full Text] [Related]
32. Oral medicinal cannabinoids to relieve symptom burden in the palliative care of patients with advanced cancer: a double-blind, placebo-controlled, randomised clinical trial of efficacy and safety of 1:1 delta-9-tetrahydrocannabinol (THC) and cannabidiol (CBD).
Hardy J; Haywood A; Gogna G; Martin J; Yates P; Greer R; Good P
Trials; 2020 Jul; 21(1):611. PubMed ID: 32631447
[TBL] [Abstract][Full Text] [Related]
33. Cannabis and Neuropsychiatric Disorders: An Updated Review.
Chayasirisobhon S
Acta Neurol Taiwan; 2019 Jun; 28(2)():27-39. PubMed ID: 31867704
[TBL] [Abstract][Full Text] [Related]
34. Cannabinoids: for better and for worse
.
Thibaut F; Hoehe MR
Dialogues Clin Neurosci; 2020 Sep; 22(3):201-204. PubMed ID: 33162763
[TBL] [Abstract][Full Text] [Related]
35. Endocannabinoid System: A Multi-Facet Therapeutic Target.
Kaur R; Ambwani SR; Singh S
Curr Clin Pharmacol; 2016; 11(2):110-7. PubMed ID: 27086601
[TBL] [Abstract][Full Text] [Related]
36. Cannabinoid tetrad effects of oral Δ9-tetrahydrocannabinol (THC) and cannabidiol (CBD) in male and female rats: sex, dose-effects and time course evaluations.
Moore CF; Weerts EM
Psychopharmacology (Berl); 2022 May; 239(5):1397-1408. PubMed ID: 34652500
[TBL] [Abstract][Full Text] [Related]
37. Adherence to Consolidated Standards of Reporting Trials (CONSORT) Guidelines for Reporting Safety Outcomes in Trials of Medical Cannabis and Cannabis-based Medicines for Chronic Noncancer Pain: A Systematic Review.
Mohiuddin MM; Mizubuti GB; Haroutounian S; Smith SM; Rice ASC; Campbell F; Park R; Gilron I
Clin J Pain; 2020 Apr; 36(4):302-319. PubMed ID: 31977375
[TBL] [Abstract][Full Text] [Related]
38. Co-exposure of cocaine and cannabinoids and its association with select biological, behavioural and health outcomes: A systematic scoping review of multi-disciplinary studies.
Daldegan-Bueno D; Maia LO; Glass M; Jutras-Aswad D; Fischer B
Eur Neuropsychopharmacol; 2021 Oct; 51():106-131. PubMed ID: 34273801
[TBL] [Abstract][Full Text] [Related]
39. A randomised controlled trial of vaporised Δ
Solowij N; Broyd S; Greenwood LM; van Hell H; Martelozzo D; Rueb K; Todd J; Liu Z; Galettis P; Martin J; Murray R; Jones A; Michie PT; Croft R
Eur Arch Psychiatry Clin Neurosci; 2019 Feb; 269(1):17-35. PubMed ID: 30661105
[TBL] [Abstract][Full Text] [Related]
40. Urinary Pharmacokinetic Profile of Cannabidiol (CBD), Δ9-Tetrahydrocannabinol (THC) and Their Metabolites following Oral and Vaporized CBD and Vaporized CBD-Dominant Cannabis Administration.
Sholler DJ; Spindle TR; Cone EJ; Goffi E; Kuntz D; Mitchell JM; Winecker RE; Bigelow GE; Flegel RR; Vandrey R
J Anal Toxicol; 2022 May; 46(5):494-503. PubMed ID: 34089060
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
